RONALD DE WIT
Holanda
Professor Ronald de Wit is Medical Oncologist, and full professor at the Erasmus MC Cancer Institute. He obtained his medical degree at the University of Amsterdam and is affiliated at the Erasmus MC since 1990. Prof de Wit is member has been serving as Faculty and Program Committee Member of both the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) for more than 2 decades.
His research focus is Genito-Urinary Oncology. He is former chairman of the EORTC-Genitourinary Group Chemotherapy Subcommittee and initiated and led randomized studies in testicular cancer, renal, prostate and bladder cancer. He co-chaired phase 3 registration trials, ranging from chemotherapy and AR targeted agents in prostate cancer, to checkpoint inhibition (PD-1) trials in bladder cancer. He is involved in a wide variety of ongoing clinical studies, was the principal investigator for the practice changing phase 3 CARD study, and serves on Industry Advisory Board Committees, as well as Data Monitoring Committees, including the recent pivotal trials in renal cancer.
Prof de Wit is collaborating with the Dpts of Urology, Tumor Immunology and Translational Pathology in preclinical and clinical translational research. He launched and is Chairman of the Dutch Uro Oncology Study Group (www.stichtingduos.nl), comprising 27 Academic and Supraregional Hospitals in the Netherlands. His publications include over 350 papers and book chapters. In 2023 he was appointed Membership of the prestigious Academy of Europe.
Holanda
Professor Ronald de Wit is Medical Oncologist, and full professor at the Erasmus MC Cancer Institute. He obtained his medical degree at the University of Amsterdam and is affiliated at the Erasmus MC since 1990. Prof de Wit is member has been serving as Faculty and Program Committee Member of both the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) for more than 2 decades.
His research focus is Genito-Urinary Oncology. He is former chairman of the EORTC-Genitourinary Group Chemotherapy Subcommittee and initiated and led randomized studies in testicular cancer, renal, prostate and bladder cancer. He co-chaired phase 3 registration trials, ranging from chemotherapy and AR targeted agents in prostate cancer, to checkpoint inhibition (PD-1) trials in bladder cancer. He is involved in a wide variety of ongoing clinical studies, was the principal investigator for the practice changing phase 3 CARD study, and serves on Industry Advisory Board Committees, as well as Data Monitoring Committees, including the recent pivotal trials in renal cancer.
Prof de Wit is collaborating with the Dpts of Urology, Tumor Immunology and Translational Pathology in preclinical and clinical translational research. He launched and is Chairman of the Dutch Uro Oncology Study Group (www.stichtingduos.nl), comprising 27 Academic and Supraregional Hospitals in the Netherlands. His publications include over 350 papers and book chapters. In 2023 he was appointed Membership of the prestigious Academy of Europe.